The FDA has cleared Rasonque, a daily pill for advanced pancreatic cancer. Clinical trials show it doubles survival rates. The drug is now available in the US at $39,800 per month, raising questions about access.
The US Food and Drug Administration has granted approval to Rasonque, a new oral medication from Revolution Medicines that has shown the ability to double survival rates in patients with metastatic pancreatic cancer. The decision follows results from a large clinical trial, positioning Rasonque as a significant development for those facing one of the most aggressive forms of cancer. The drug, based on daraxonrasib, is intended for daily use and is specifically targeted at patients who have already undergone previous treatments or are unable to receive combination chemotherapy.
Rasonque works by blocking multiple forms of the RAS protein, a key driver of tumor growth in pancreatic cancer. Revolution Medicines has set the price at $39,800 for a 30-day supply in the United States, a figure that has already sparked discussion about affordability and insurance coverage. The company has stated it will provide assistance programs for eligible patients. When the clinical trial results were first announced in April, demand for the drug surged, prompting the FDA to grant early access through its compassionate use program. This allowed some patients to begin treatment before full regulatory approval, with several reporting relief from the harsh side effects of chemotherapy.
The FDA's decision came through its accelerated review pathway, which has reduced the typical approval timeline from nearly a year to just a few months for certain breakthrough therapies. Revolution Medicines' CEO, Mark Goldsmith, described the approval as the culmination of more than a decade of research focused on RAS-driven pancreatic cancer, an area long considered one of the most challenging in oncology and drug development.
Investor interest in Revolution Medicines has soared, with the company's stock rising 166% since the start of the year. Analysts now project that Rasonque could eventually generate up to $11.5 billion in annual global sales. According to the American Cancer Society, approximately 67,350 new cases of pancreatic cancer are expected to be diagnosed in the US this year, underscoring the urgent need for more effective treatments.
Access to innovative therapies remains a pressing issue in the broader healthcare landscape. In Spain, for example, delays in public hospital treatment have led many patients to seek private care, as highlighted in a recent report on rising surgical waiting lists in Madrid. The introduction of high-cost drugs like Rasonque raises further questions about how health systems will manage both demand and equity of access, especially as new therapies emerge at premium prices.
Pancreatic cancer is known for its poor prognosis and limited treatment options, with most cases diagnosed at an advanced stage. The arrival of Rasonque marks a rare advance in a field where progress has been slow. However, the high cost and the challenge of integrating such therapies into public health systems remain unresolved. As more breakthrough drugs reach the market, the debate over pricing, access, and long-term sustainability in oncology is likely to intensify, both in the US and across Europe.
